Home › NCT07227922
Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
RecruitingPhase 1Healthy volunteers welcome
Who can join
Ages 18 to 83 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Male and female participants with stable moderate renal impairment (estimated glomerular filtration rate \[eGFR\]: 30 to \<60 mL/min) and matched (by sex, age, and weight) control participants with normal renal function (eGFR: ≥90 mL/min) will be enrolled in this trial. Exclusion Criteria: * Participant whose current or recent medical conditions, medications, or procedures could increase participant's safety risk, or whom the Investigator considers not suitable for entry into the trial or the participant, or who has clinically significant abnormal 12-lead electrocardiogram (ECG)/ vital sign measurements/ laboratory test results at Screening and Check-in, will not be enrolled
About the study
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
What is being tested
- 12mg clofutriben (drug)
Sponsor: Sparrow Pharmaceuticals · Participants: 16 · Started: Nov 30, 2025
Contact the study team
Official record on ClinicalTrials.gov — NCT07227922
Locations in the U.S.
| Florida | Orlando Clinical Research Center, Orlando |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.